SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

AVH AVITA Medical, Inc.

Healthcare · Medical Devices · website · 226 employees
$3.52
52wk 1.00 – 3.53
Overall
54.0
Value
87.3
Growth
80.7
Health
0.0
Quality
0.0
Momentum
99.9
Dividend
—
Price
About AVITA Medical, Inc.

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Price analytics

Returns

1 day 2.9%
1 week 6.0%
1 month 16.9%
3 months 145.3%
6 months 198.3%
1 year 112.0%
3 years -1.4%

Risk

Volatility (1y ann.) 77.5%
Beta vs ASX 200 1.00
Sharpe (1y) 1.28
VaR 95% (1-day) -5.1%
Max drawdown (1y) -39.1%
Off 1-year high 0.0%

Technicals

RSI(14) 85 OB
vs 50DMA 39.0%
vs 200DMA 129.0%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 87.3
Trailing P/E
—
Forward P/E
100
PEG ratio
89
EV / EBITDA
100
Price / Book
100
Price / Sales
30
Growth 80.7
Revenue growth (1y)
61
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow) 0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 99.9
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
100
Position in 52-week range
100

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$544.31M
P/E (trailing)
—
P/E (forward)
-11.05
EPS (trailing)
-0.41
Dividend yield
—
Payout ratio
0.0%
Beta
2.02
EV / EBITDA
-4.46
Price / Book
-2.78
ROE
—
Operating margin
-31.6%
Net margin
-57.0%
Total cash
$11.13M
Total debt
$48.48M
Current ratio
0.41
Debt / Equity
—
Free cash flow
$-13.35M
Avg volume
510,028
Latest annual results (FY ending 31 Dec 2025)
  • Revenue$71.61M
  • Gross profit$58.82M
  • Operating income-$42.53M
  • Net income-$48.59M
  • Diluted EPS-0.35
  • Free cash flow-$32.93M
  • Net debt$35.80M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4